Adverse outcome analyses of observational data: assessing cardiovascular risk in HIV disease
- PMID: 22095570
- PMCID: PMC3258276
- DOI: 10.1093/cid/cir829
Adverse outcome analyses of observational data: assessing cardiovascular risk in HIV disease
Abstract
Clinical decisions are ideally based on randomized trials but must often rely on observational data analyses, which are less straightforward and more influenced by methodology. The authors, from a series of expert roundtables convened by the Forum for Collaborative HIV Research on the use of observational studies to assess cardiovascular disease risk in human immunodeficiency virus infection, recommend that clinicians who review or interpret epidemiological publications consider 7 key statistical issues: (1) clear explanation of confounding and adjustment; (2) handling and impact of missing data; (3) consistency and clinical relevance of outcome measurements and covariate risk factors; (4) multivariate modeling techniques including time-dependent variables; (5) how multiple testing is addressed; (6) distinction between statistical and clinical significance; and (7) need for confirmation from independent databases. Recommendations to permit better understanding of potential methodological limitations include both responsible public access to de-identified source data, where permitted, and exploration of novel statistical methods.
References
-
- US Department of Health and Human Services: Panel on Antiretroviral Guidelines for Adults and Adolescents. Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents. 2011. pp. 1–166.
-
- D’Agostino RB, Kwan H. Measuring effectiveness. What to expect without a randomized control group. Med Care. 1995;33:AS95–105. - PubMed
-
- 21 U.S.C. § 355(k)
-
- ICH Harmonised Tripartite Guideline. Statistical principles for clinical trials. International Conference on Harmonisation E9 Expert Working Group. Stat Med. 1999;18:1905–42. - PubMed
-
- International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use. 2004. ICH Harmonised Tripartite Guideline. Pharmacovigilance planning— sections 3.2.1/Annex 4.
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Medical
